S&P 500   4,564.49 (+0.21%)
DOW   35,552.62 (+0.38%)
QQQ   390.90 (+0.18%)
AAPL   189.37 (-0.54%)
MSFT   379.23 (-0.91%)
META   332.81 (-1.82%)
GOOGL   135.34 (-1.36%)
AMZN   146.77 (-0.18%)
TSLA   246.22 (-0.20%)
NVDA   481.45 (+0.68%)
NIO   7.21 (+0.00%)
BABA   74.90 (-2.40%)
AMD   124.55 (+2.08%)
T   16.32 (+0.87%)
F   10.66 (+2.80%)
MU   76.80 (+0.89%)
CGC   0.57 (+4.89%)
GE   119.25 (+0.34%)
DIS   93.07 (+0.62%)
AMC   7.22 (+7.76%)
PFE   30.12 (+1.45%)
PYPL   58.41 (-0.10%)
XOM   103.63 (-0.26%)
S&P 500   4,564.49 (+0.21%)
DOW   35,552.62 (+0.38%)
QQQ   390.90 (+0.18%)
AAPL   189.37 (-0.54%)
MSFT   379.23 (-0.91%)
META   332.81 (-1.82%)
GOOGL   135.34 (-1.36%)
AMZN   146.77 (-0.18%)
TSLA   246.22 (-0.20%)
NVDA   481.45 (+0.68%)
NIO   7.21 (+0.00%)
BABA   74.90 (-2.40%)
AMD   124.55 (+2.08%)
T   16.32 (+0.87%)
F   10.66 (+2.80%)
MU   76.80 (+0.89%)
CGC   0.57 (+4.89%)
GE   119.25 (+0.34%)
DIS   93.07 (+0.62%)
AMC   7.22 (+7.76%)
PFE   30.12 (+1.45%)
PYPL   58.41 (-0.10%)
XOM   103.63 (-0.26%)
S&P 500   4,564.49 (+0.21%)
DOW   35,552.62 (+0.38%)
QQQ   390.90 (+0.18%)
AAPL   189.37 (-0.54%)
MSFT   379.23 (-0.91%)
META   332.81 (-1.82%)
GOOGL   135.34 (-1.36%)
AMZN   146.77 (-0.18%)
TSLA   246.22 (-0.20%)
NVDA   481.45 (+0.68%)
NIO   7.21 (+0.00%)
BABA   74.90 (-2.40%)
AMD   124.55 (+2.08%)
T   16.32 (+0.87%)
F   10.66 (+2.80%)
MU   76.80 (+0.89%)
CGC   0.57 (+4.89%)
GE   119.25 (+0.34%)
DIS   93.07 (+0.62%)
AMC   7.22 (+7.76%)
PFE   30.12 (+1.45%)
PYPL   58.41 (-0.10%)
XOM   103.63 (-0.26%)
S&P 500   4,564.49 (+0.21%)
DOW   35,552.62 (+0.38%)
QQQ   390.90 (+0.18%)
AAPL   189.37 (-0.54%)
MSFT   379.23 (-0.91%)
META   332.81 (-1.82%)
GOOGL   135.34 (-1.36%)
AMZN   146.77 (-0.18%)
TSLA   246.22 (-0.20%)
NVDA   481.45 (+0.68%)
NIO   7.21 (+0.00%)
BABA   74.90 (-2.40%)
AMD   124.55 (+2.08%)
T   16.32 (+0.87%)
F   10.66 (+2.80%)
MU   76.80 (+0.89%)
CGC   0.57 (+4.89%)
GE   119.25 (+0.34%)
DIS   93.07 (+0.62%)
AMC   7.22 (+7.76%)
PFE   30.12 (+1.45%)
PYPL   58.41 (-0.10%)
XOM   103.63 (-0.26%)

Fresenius Medical Care AG & Co. KGaA Stock Price, News & Analysis (NYSE:FMS)

$20.53
+0.12 (+0.59%)
(As of 02:09 PM ET)
Compare
Today's Range
$20.42
$20.59
50-Day Range
$16.40
$23.09
52-Week Range
$15.28
$27.72
Volume
180,400 shs
Average Volume
653,545 shs
Market Capitalization
$12.05 billion
P/E Ratio
25.04
Dividend Yield
2.05%
Price Target
$17.85

Fresenius Medical Care AG & Co. KGaA MarketRank™ Stock Analysis

Analyst Rating
Hold
2.11 Rating Score
Upside/​Downside
12.9% Downside
$17.85 Price Target
Short Interest
Healthy
0.21% of Shares Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
N/A
News Sentiment
1.45mentions of Fresenius Medical Care AG & Co. KGaA in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
26.98%
From $1.26 to $1.60 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.35 out of 5 stars

Medical Sector

248th out of 949 stocks

Miscellaneous Health & Allied Services, Not Elsewhere Classified Industry

2nd out of 7 stocks


FMS stock logo

About Fresenius Medical Care AG & Co. KGaA Stock (NYSE:FMS)

Fresenius Medical Care AG & Co. KGaA provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. It also develops, manufactures, and distributes various health care products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.

FMS Stock Price History

FMS Stock News Headlines

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
The Only Practical Solution to the World’s Looming Energy Crisis
There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!
Novo Nordisk stock pops on Ozempic kidney trial success
Here's Why You Should Retain Fresenius Medical (FMS) for Now
See More Headlines
Receive FMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fresenius Medical Care AG & Co. KGaA and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/01/2023
Today
11/29/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/20/2024

Industry, Sector and Symbol

Industry
Miscellaneous health & allied services, not elsewhere classified
Sub-Industry
N/A
Sector
Medical
Employees
1,235
Year Founded
1912

Price Target and Rating

Average Stock Price Target
$17.85
High Stock Price Target
$24.00
Low Stock Price Target
$11.70
Potential Upside/Downside
-13.0%
Consensus Rating
Hold
Rating Score (0-4)
2.11
Research Coverage
9 Analysts

Profitability

Net Income
$709.50 million
Pretax Margin
4.99%

Debt

Sales & Book Value

Annual Sales
$20.44 billion
Cash Flow
$5.02 per share
Book Value
$28.63 per share

Miscellaneous

Free Float
N/A
Market Cap
$12.04 billion
Optionable
Optionable
Beta
1.04

Social Links

Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Ms. Helen Giza (Age 55)
    CEO & Chair of Management Board of Fresenius Med. Care Mgmt AG
    Comp: $3.49M
  • Dr. Franklin W. Maddux F.A.C.P. (Age 66)
    Global Chief Medical Officer & Member of Management Board of Fresenius Medical Care Management AG
    Comp: $2.62M
  • Mr. William J. Valle (Age 63)
    Management Board Member for Care Delivery of Fresenius Medical Care Management AG
    Comp: $4.27M
  • Dr. Katarzyna Mazur-Hofsab Ph.D. (Age 60)
    Management Board Member for Care Enablement of Fresenius Medical Care Management AG
    Comp: $2.54M
  • Mr. Roberto Fuste (Age 71)
    Executive Advisor for Regional Strategy
  • Mr. Martin Fischer (Age 46)
    CFO & Member of the Management Board of Fresenius Medical Care Management AG
  • Dr. Dominik Heger
    Executive VP and Head of Investor Relations, Strategic Development & Communications
  • Mr. Borries Von Muller (Age 62)
    Senior Vice President of Global Human Resources Employee Communications
  • Mr. Joachim Weith
    Senior Vice President of Corporate Communications & Governmental Affairs
  • Mr. Oliver Maier
    Senior Vice President Investor Relations














FMS Stock Analysis - Frequently Asked Questions

Should I buy or sell Fresenius Medical Care AG & Co. KGaA stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fresenius Medical Care AG & Co. KGaA in the last year. There are currently 1 sell rating, 6 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" FMS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FMS, but not buy additional shares or sell existing shares.
View FMS analyst ratings
or view top-rated stocks.

What is Fresenius Medical Care AG & Co. KGaA's stock price target for 2024?

9 equities research analysts have issued 1 year target prices for Fresenius Medical Care AG & Co. KGaA's shares. Their FMS share price targets range from $11.70 to $24.00. On average, they anticipate the company's stock price to reach $17.85 in the next twelve months. This suggests that the stock has a possible downside of 12.9%.
View analysts price targets for FMS
or view top-rated stocks among Wall Street analysts.

How have FMS shares performed in 2023?

Fresenius Medical Care AG & Co. KGaA's stock was trading at $16.34 at the beginning of the year. Since then, FMS stock has increased by 25.4% and is now trading at $20.49.
View the best growth stocks for 2023 here
.

Are investors shorting Fresenius Medical Care AG & Co. KGaA?

Fresenius Medical Care AG & Co. KGaA saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 1,250,000 shares, a decline of 41.6% from the October 31st total of 2,140,000 shares. Based on an average trading volume of 575,200 shares, the short-interest ratio is presently 2.2 days.
View Fresenius Medical Care AG & Co. KGaA's Short Interest
.

When is Fresenius Medical Care AG & Co. KGaA's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 20th 2024.
View our FMS earnings forecast
.

How were Fresenius Medical Care AG & Co. KGaA's earnings last quarter?

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) issued its quarterly earnings data on Wednesday, November, 1st. The company reported $0.31 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.37 by $0.06. The firm had revenue of $5.37 billion for the quarter, compared to analyst estimates of $5.42 billion. Fresenius Medical Care AG & Co. KGaA had a trailing twelve-month return on equity of 4.85% and a net margin of 2.30%. During the same period in the prior year, the business earned $0.40 EPS.

How often does Fresenius Medical Care AG & Co. KGaA pay dividends? What is the dividend yield for Fresenius Medical Care AG & Co. KGaA?

Fresenius Medical Care AG & Co. KGaA announced an annual dividend on Wednesday, May 3rd. Shareholders of record on Thursday, May 18th will be paid a dividend of $0.7086 per share on Thursday, June 1st. This represents a yield of 2.1%. The ex-dividend date of this dividend is Wednesday, May 17th.
Read our dividend analysis for FMS
.

Is Fresenius Medical Care AG & Co. KGaA a good dividend stock?

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) pays an annual dividend of $0.42 per share and currently has a dividend yield of 2.06%. The dividend payout ratio is 51.22%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, FMS will have a dividend payout ratio of 26.25% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for FMS.

What ETFs hold Fresenius Medical Care AG & Co. KGaA's stock?

ETFs with the largest weight of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) stock in their portfolio include Invesco International Dividend Achievers ETF (PID).Cultivar ETF (CVAR).

What other stocks do shareholders of Fresenius Medical Care AG & Co. KGaA own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fresenius Medical Care AG & Co. KGaA investors own include Energy Transfer (ET), Petra Diamonds (PDL), AT&T (T), Pfizer (PFE), AbbVie (ABBV), Gilead Sciences (GILD), Merck & Co., Inc. (MRK), Abbott Laboratories (ABT), Chevron (CVX) and Ford Motor (F).

Who are Fresenius Medical Care AG & Co. KGaA's major shareholders?

Fresenius Medical Care AG & Co. KGaA's stock is owned by a number of institutional and retail investors. Top institutional investors include Pzena Investment Management LLC (2.78%), Morgan Stanley (0.18%), Invesco Ltd. (0.14%), Envestnet Asset Management Inc. (0.04%), Northern Trust Corp (0.04%) and O Shaughnessy Asset Management LLC (0.02%).

How do I buy shares of Fresenius Medical Care AG & Co. KGaA?

Shares of FMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does Fresenius Medical Care AG & Co. KGaA have any subsidiaries?
The following companies are subsidiares of Fresenius Medical Care AG & Co. KGaA: NxStage Medical.
Read More
This page (NYSE:FMS) was last updated on 11/29/2023 by MarketBeat.com Staff

My Account -